Literature DB >> 8889289

Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain.

A C Pande1, R E Pyke, M Greiner, G L Wideman, R Benjamin, M W Pierce.   

Abstract

Enadoline, a selective agonist of the kappa-opioid receptor, was studied for its analgesic efficacy in patients with pain after obstetric or gynecologic surgery. An initial study involving a comparison of enadoline (2, 5, 15 micrograms), an acetaminophen-codeine (ACET/COD) combination, and placebo showed all treatments to be ineffective analgesics. Therefore, a second study with the same design but using higher doses of enadoline (15 and 25 micrograms) and replacing ACET/COD with morphine 10 mg i.m. was conducted. Enadoline 25 micrograms produced similar pain relief to that of morphine, although of shorter duration, and better than enadoline 15 micrograms or placebo. However, enadoline was associated with dose-limiting neuropsychiatric adverse events, which led to early termination of the study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889289     DOI: 10.1097/00002826-199619050-00009

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  22 in total

1.  Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in rats.

Authors:  S Stevens Negus; Robert O'Connell; Ember Morrissey; Kejun Cheng; Kenner C Rice
Journal:  J Pharmacol Exp Ther       Date:  2011-11-29       Impact factor: 4.030

2.  75 years of opioid research: the exciting but vain quest for the Holy Grail.

Authors:  Alistair D Corbett; Graeme Henderson; Alexander T McKnight; Stewart J Paterson
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 3.  Emerging Treatment Targets for Migraine and Other Headaches.

Authors:  Zachariah Bertels; Amynah Amir Ali Pradhan
Journal:  Headache       Date:  2019-07       Impact factor: 5.887

4.  Sex differences in kappa opioid receptor inhibition of latent postoperative pain sensitization in dorsal horn.

Authors:  Lilian Custodio-Patsey; Renée R Donahue; Weisi Fu; Joshua Lambert; Bret N Smith; Bradley K Taylor
Journal:  Neuropharmacology       Date:  2019-07-25       Impact factor: 5.250

5.  A method for conducting functional MRI studies in alert nonhuman primates: initial results with opioid agonists in male cynomolgus monkeys.

Authors:  Marc J Kaufman; Amy C Janes; Blaise deB Frederick; Melanie Brimson-Théberge; Yunjie Tong; Samuel B McWilliams; Ashley Bear; Timothy E Gillis; Katrina M Schrode; Perry F Renshaw; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2013-06-17       Impact factor: 3.157

Review 6.  Amygdala, neuropeptides, and chronic pain-related affective behaviors.

Authors:  Volker Neugebauer; Mariacristina Mazzitelli; Bryce Cragg; Guangchen Ji; Edita Navratilova; Frank Porreca
Journal:  Neuropharmacology       Date:  2020-03-15       Impact factor: 5.250

7.  Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion.

Authors:  Jeffrey J Liu; Yi-Ting Chiu; Kelly M DiMattio; Chongguang Chen; Peng Huang; Taylor A Gentile; John W Muschamp; Alan Cowan; Matthias Mann; Lee-Yuan Liu-Chen
Journal:  Neuropsychopharmacology       Date:  2018-07-20       Impact factor: 7.853

8.  Expression and pharmacological modulation of visceral pain-induced conditioned place aversion in mice.

Authors:  Deniz Bagdas; Pretal P Muldoon; Shakir AlSharari; F Ivy Carroll; S Stevens Negus; M Imad Damaj
Journal:  Neuropharmacology       Date:  2015-11-27       Impact factor: 5.250

Review 9.  Single dose oral paracetamol (acetaminophen) with codeine for postoperative pain in adults.

Authors:  Laurence Toms; Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

10.  Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats.

Authors:  S Stevens Negus; Ember M Morrissey; Marisa Rosenberg; K Cheng; Kenner C Rice
Journal:  Psychopharmacology (Berl)       Date:  2010-01-26       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.